Atrial fibrillation and cardiac resynchronization therapy: The MASCOT study

Luigi Padeletti, Nicola Musilli, Maria Cristina Porciani, Andrea Colella, Luigi Di Biase, Giuseppe Ricciardi, Paolo Pieragnoli, Antonio Michelucci, GianFranco F. Gensini

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Atrial fibrillation (AF) and congestive heart failure (CHF) share several characteristics and often coexist in the same patient. Both are responsible for significant morbidity and mortality, are increasing in prevalence, and are major sources of health expenditure. The Management of Atrial fibrillation Suppression in AF-HF COmorbidity Therapy (MASCOT) study is a European, single-blind, prospective, controlled, multicentre, randomized clinical trial designed to examine whether adding the AF Suppression™ Algorithm to cardiac resynchronization therapy (CRT) improves the prognosis of patients with CHF. The patients will be randomly assigned to a CRT-only group, with the AF Suppression™ algorithm programmed OFF (control group), versus a CRT + AF Suppression™ group, with the algorithm programmed ON (treatment group). The primary study endpoint is development of permanent AF, and secondary endpoints are safety of the AF Suppression™ algorithm, and evolution of multiple clinical variables over 24 months of follow-up. CRT combined with a refined atrial tachyarrhythmia prevention pacing algorithm may represent a major advance in the management of AF and CHF by electrical stimulation.

Original languageEnglish (US)
JournalEuropace
Volume5
Issue numberSUPPL. 1
DOIs
StatePublished - Sep 2004
Externally publishedYes

Fingerprint

Cardiac Resynchronization Therapy
Atrial Fibrillation
Heart Failure
Health Expenditures
Tachycardia
Electric Stimulation
Comorbidity
Randomized Controlled Trials
Morbidity
Safety
Control Groups
Mortality

Keywords

  • Atrial fibrillation
  • Atrial pacing
  • Cardiac resynchronization therapy
  • Overdrive pacing

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Padeletti, L., Musilli, N., Porciani, M. C., Colella, A., Di Biase, L., Ricciardi, G., ... Gensini, G. F. (2004). Atrial fibrillation and cardiac resynchronization therapy: The MASCOT study. Europace, 5(SUPPL. 1). https://doi.org/10.1016/j.eupc.2004.07.007

Atrial fibrillation and cardiac resynchronization therapy : The MASCOT study. / Padeletti, Luigi; Musilli, Nicola; Porciani, Maria Cristina; Colella, Andrea; Di Biase, Luigi; Ricciardi, Giuseppe; Pieragnoli, Paolo; Michelucci, Antonio; Gensini, GianFranco F.

In: Europace, Vol. 5, No. SUPPL. 1, 09.2004.

Research output: Contribution to journalArticle

Padeletti, L, Musilli, N, Porciani, MC, Colella, A, Di Biase, L, Ricciardi, G, Pieragnoli, P, Michelucci, A & Gensini, GF 2004, 'Atrial fibrillation and cardiac resynchronization therapy: The MASCOT study', Europace, vol. 5, no. SUPPL. 1. https://doi.org/10.1016/j.eupc.2004.07.007
Padeletti L, Musilli N, Porciani MC, Colella A, Di Biase L, Ricciardi G et al. Atrial fibrillation and cardiac resynchronization therapy: The MASCOT study. Europace. 2004 Sep;5(SUPPL. 1). https://doi.org/10.1016/j.eupc.2004.07.007
Padeletti, Luigi ; Musilli, Nicola ; Porciani, Maria Cristina ; Colella, Andrea ; Di Biase, Luigi ; Ricciardi, Giuseppe ; Pieragnoli, Paolo ; Michelucci, Antonio ; Gensini, GianFranco F. / Atrial fibrillation and cardiac resynchronization therapy : The MASCOT study. In: Europace. 2004 ; Vol. 5, No. SUPPL. 1.
@article{e395df30e24246e391827c96e4e3b389,
title = "Atrial fibrillation and cardiac resynchronization therapy: The MASCOT study",
abstract = "Atrial fibrillation (AF) and congestive heart failure (CHF) share several characteristics and often coexist in the same patient. Both are responsible for significant morbidity and mortality, are increasing in prevalence, and are major sources of health expenditure. The Management of Atrial fibrillation Suppression in AF-HF COmorbidity Therapy (MASCOT) study is a European, single-blind, prospective, controlled, multicentre, randomized clinical trial designed to examine whether adding the AF Suppression™ Algorithm to cardiac resynchronization therapy (CRT) improves the prognosis of patients with CHF. The patients will be randomly assigned to a CRT-only group, with the AF Suppression™ algorithm programmed OFF (control group), versus a CRT + AF Suppression™ group, with the algorithm programmed ON (treatment group). The primary study endpoint is development of permanent AF, and secondary endpoints are safety of the AF Suppression™ algorithm, and evolution of multiple clinical variables over 24 months of follow-up. CRT combined with a refined atrial tachyarrhythmia prevention pacing algorithm may represent a major advance in the management of AF and CHF by electrical stimulation.",
keywords = "Atrial fibrillation, Atrial pacing, Cardiac resynchronization therapy, Overdrive pacing",
author = "Luigi Padeletti and Nicola Musilli and Porciani, {Maria Cristina} and Andrea Colella and {Di Biase}, Luigi and Giuseppe Ricciardi and Paolo Pieragnoli and Antonio Michelucci and Gensini, {GianFranco F.}",
year = "2004",
month = "9",
doi = "10.1016/j.eupc.2004.07.007",
language = "English (US)",
volume = "5",
journal = "Europace",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Atrial fibrillation and cardiac resynchronization therapy

T2 - The MASCOT study

AU - Padeletti, Luigi

AU - Musilli, Nicola

AU - Porciani, Maria Cristina

AU - Colella, Andrea

AU - Di Biase, Luigi

AU - Ricciardi, Giuseppe

AU - Pieragnoli, Paolo

AU - Michelucci, Antonio

AU - Gensini, GianFranco F.

PY - 2004/9

Y1 - 2004/9

N2 - Atrial fibrillation (AF) and congestive heart failure (CHF) share several characteristics and often coexist in the same patient. Both are responsible for significant morbidity and mortality, are increasing in prevalence, and are major sources of health expenditure. The Management of Atrial fibrillation Suppression in AF-HF COmorbidity Therapy (MASCOT) study is a European, single-blind, prospective, controlled, multicentre, randomized clinical trial designed to examine whether adding the AF Suppression™ Algorithm to cardiac resynchronization therapy (CRT) improves the prognosis of patients with CHF. The patients will be randomly assigned to a CRT-only group, with the AF Suppression™ algorithm programmed OFF (control group), versus a CRT + AF Suppression™ group, with the algorithm programmed ON (treatment group). The primary study endpoint is development of permanent AF, and secondary endpoints are safety of the AF Suppression™ algorithm, and evolution of multiple clinical variables over 24 months of follow-up. CRT combined with a refined atrial tachyarrhythmia prevention pacing algorithm may represent a major advance in the management of AF and CHF by electrical stimulation.

AB - Atrial fibrillation (AF) and congestive heart failure (CHF) share several characteristics and often coexist in the same patient. Both are responsible for significant morbidity and mortality, are increasing in prevalence, and are major sources of health expenditure. The Management of Atrial fibrillation Suppression in AF-HF COmorbidity Therapy (MASCOT) study is a European, single-blind, prospective, controlled, multicentre, randomized clinical trial designed to examine whether adding the AF Suppression™ Algorithm to cardiac resynchronization therapy (CRT) improves the prognosis of patients with CHF. The patients will be randomly assigned to a CRT-only group, with the AF Suppression™ algorithm programmed OFF (control group), versus a CRT + AF Suppression™ group, with the algorithm programmed ON (treatment group). The primary study endpoint is development of permanent AF, and secondary endpoints are safety of the AF Suppression™ algorithm, and evolution of multiple clinical variables over 24 months of follow-up. CRT combined with a refined atrial tachyarrhythmia prevention pacing algorithm may represent a major advance in the management of AF and CHF by electrical stimulation.

KW - Atrial fibrillation

KW - Atrial pacing

KW - Cardiac resynchronization therapy

KW - Overdrive pacing

UR - http://www.scopus.com/inward/record.url?scp=4444227512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444227512&partnerID=8YFLogxK

U2 - 10.1016/j.eupc.2004.07.007

DO - 10.1016/j.eupc.2004.07.007

M3 - Article

C2 - 15450280

AN - SCOPUS:4444227512

VL - 5

JO - Europace

JF - Europace

SN - 1099-5129

IS - SUPPL. 1

ER -